BioMimetic Therapeutics, Inc.  

(Public, NASDAQ:BMTI)   Watch this stock  
Find more results for BMTI
NASDAQ real-time data - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 268.23M
P/E     -
Div/yield     -
EPS -0.96
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -667.77% -1924.11%
Operating margin -669.84% -1929.91%
EBITD margin - -1684.51%
Return on average assets -31.13% -36.79%
Return on average equity -44.75% -48.41%
Employees 75 -
CDP Score - -


389 Nichol Mill Lane
United States - Map
+1-615-8441280 (Phone)
+1-615-8441281 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company�s Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company�s product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.